Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms HLX 31 |
Target |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Preclinical | TW | 01 May 2016 |